3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Hepatitis C
4
Carcinoma, Hepatocellular
4
Recurrence
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Respiratory Tract Infections
2
Lymphoma, Mantle-Cell
2
Infections
2
Hepatitis C, Chronic
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Testicular Neoplasms
1
Teratoma, Testicular
1
Teratoma
1
Seminoma
1
Respiratory Syncytial Virus Infections
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pneumonia
1
Neuroblastoma
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Malignant Solid Tumor
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Cyclophosphamide
254
fludarabine phosphate
165
Cytarabine
160
Methotrexate
128
Busulfan
115
Filgrastim
111
fludarabine
102
Peripheral Blood Stem Cell Transplantation
96
Rituximab
94
Antilymphocyte Serum
83
Etoposide
81
Cyclosporine
75
Tacrolimus
74
Mycophenolic Acid
73
Whole-Body Irradiation
72
Radiotherapy
70
Melphalan
66
Vincristine
55
Dexamethasone
54
Granulocyte Colony-Stimulating Factor
50
Methylprednisolone
48
Azacitidine
44
Alemtuzumab
42
Imatinib Mesylate
41
Clofarabine
41
sargramostim
40
Idarubicin
36
Daunorubicin
36
Cord Blood Stem Cell Transplantation
36
Mercaptopurine
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia
×
Ribavirin
×
Clear all
NCT00559091
2022-12-22
Borden-001
Jewish General Hospital
Phase 2
Completed
18 enrolled